BidaskClub Upgrades Alexion Pharmaceuticals (NASDAQ:ALXN) to “Hold”
ALXN has been the subject of several other reports. Wedbush assumed coverage on Alexion Pharmaceuticals in a report on Wednesday, May 22nd. They issued an outperform rating and a $173.00 target price for the company. Citigroup dropped their target price on Alexion Pharmaceuticals from $180.00 to $165.00 and set a buy rating for the company in a report on Thursday, May 23rd. Royal Bank of Canada restated an outperform rating and issued a $186.00 target price (up from $165.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, March 27th. Guggenheim assumed coverage on Alexion Pharmaceuticals in a report on Friday, February 22nd. They issued a neutral rating and a $135.00 target price for the company. Finally, Raymond James assumed coverage on Alexion Pharmaceuticals in a report on Wednesday, April 10th. They issued an outperform rating and a $161.00 target price for the company. Seven equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The company currently has an average rating of Buy and an average price target of $161.06.
Shares of NASDAQ:ALXN opened at $117.93 on Thursday. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.87 and a quick ratio of 3.36. The firm has a market capitalization of $26.44 billion, a price-to-earnings ratio of 14.97, a P/E/G ratio of 0.88 and a beta of 1.58. Alexion Pharmaceuticals has a 52-week low of $92.56 and a 52-week high of $141.86.
In other news, Director Bros. Advisors Lp Baker sold 123,489 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $126.53, for a total value of $15,625,063.17. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 4.08% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Investors Research Corp acquired a new position in Alexion Pharmaceuticals during the 1st quarter worth about $27,000. Thor Advisors LLC acquired a new position in Alexion Pharmaceuticals during the 1st quarter worth about $34,000. Institutional & Family Asset Management LLC lifted its stake in Alexion Pharmaceuticals by 39.5% during the 1st quarter. Institutional & Family Asset Management LLC now owns 307 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 87 shares in the last quarter. Captrust Financial Advisors acquired a new position in Alexion Pharmaceuticals during the 4th quarter worth about $31,000. Finally, Berman Capital Advisors LLC lifted its stake in Alexion Pharmaceuticals by 68.6% during the 1st quarter. Berman Capital Advisors LLC now owns 322 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 131 shares in the last quarter. 94.51% of the stock is currently owned by institutional investors and hedge funds.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Read More: Back-End Load
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.